1. Scrip
  2. >>Archive

New C$50 venture fund gets Merck a first look at new technologies in Quebec

 
• By Mandy Jackson

Merck launched the Merck Lumira Bioscience Fund on 26 March with C$35 million to support venture capital investment in early stage biotechnology companies based in or considering a move to Quebec, Canada. The investment doesn't buy Merck any first right of refusal to partner with the Quebec startups, but it will get the first look at the early stage companies' technology. To acquire or license intellectual property, Merck will have to make separate arrangements outside of the venture funding contracts.

Merck launched the Merck Lumira Bioscience Fund on 26 March with C$35 million to support venture capital investment in early stage biotechnology companies based in or considering a move to Quebec, Canada. The investment doesn't buy Merck any first right of refusal to partner with the Quebec startups, but it will get the first look at the early stage companies' technology. To acquire or license intellectual property, Merck will have to make separate arrangements outside of the venture funding contracts.

Including Merck's contribution, the venture fund managed by Lumira Capital in Montreal has C$43 million, but the fund's target is C$50 million

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’